Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

ed significant improvements in physical function, as measured by the Health Assessment Questionnaire (HAQ). HAQ assesses the degree of difficulty a person has in accomplishing tasks in eight functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and other activities of daily living).

At week 24, the proportion of patients experiencing clinically relevant improvement (increase in HAQ score of at least 0.25 from baseline) was significantly greater for golimumab-treated patients compared with those receiving placebo. More than half of patients in the combined golimumab group (52 percent) achieved the measure, compared with 34 percent of placebo-treated patients (P < 0.001). Also at week 24, patients receiving golimumab experienced a mean improvement in HAQ of 0.27 +/- 0.51, compared with an improvement of 0.05 +/- 0.51 among patients receiving placebo (P < 0.001). Importantly, among patients whose prior anti-TNF therapy was discontinued due to lack of efficacy, golimumab-treated patients experienced a mean improvement of 0.23 +/- 0.50 in HAQ, compared with an average improvement of 0.06 +/- 0.51 for patients receiving placebo (P < 0.05).

At week 24, the combined golimumab group also experienced significantly greater mean improvement in fatigue, 6.8 +/- 11.4, compared with an improvement of 3.0 +/- 9.7 among patients treated with placebo (P < 0.001). Patients were evaluated with the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), a 13-item questionnaire that assesses self-reported fatigue and its impact on daily activities and function.

Improvements Seen in Patients Previously Treated with Methotrexate

A second Phase 3 study also presented at ACR evaluated 50 mg and 100 mg doses of golimumab in RA patients who had active RA and were previously treated with methotrexate. In GOlimumab FOR subjects With Active RA Despite Methotrexate (GO-FORWARD), patients also indicated significant improvement in f
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... The identification of protein-coding variants underlying ... by exome sequencing. Built on Roche NimbleGen’s proprietary ... EZ Developer system has been a proven tool ... present how he achieved coverage statistics similar to ... exome kits. With over 236,000 SNPs and over ...
(Date:8/21/2014)... 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... U.S. and XIAPEX ® in the EU, ... randomized, double-blind Phase 2a study of CCH for ... panniculopathy. The results showed that all three doses ...
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... Fertilizer Industry” is a professional and in-depth ... The report provides basic Seaweed Fertilizer information, ... industry chain structure as well as industry ... analysis, including domestic market as well as ...
Breaking Biology Technology:Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... Elizabeth P. Roquemore, Sam Murphy, *Stephen ... Swinburne , , ... 9NA England, , ... throughput imaging systems, analysis algorithms and associated,cellular assays have begun to be used ...
... , Key words: ... LC-MS/MS • DeCyder MS • differential analysis, ... was used in conjunction with tandem mass spectrometry (MS/MS) to separate ... tree, Olea europaea . DeCyder™ MS Differential Analysis Software (DeCyder ...
... Karlsson, and H. Lindgren , ... Sweden , , ... columns prepacked with Ni Sepharose 6 Fast Flow without the need for a ... the highest available on the market, and separations can be completed in as ...
Cached Biology Technology:Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 2Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 3Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 4Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 2Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 3Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 4Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 5Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 6Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 7Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 8Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 9New gravity-flow column gives faster and simpler purification of histidine-tagged proteins 2New gravity-flow column gives faster and simpler purification of histidine-tagged proteins 3New gravity-flow column gives faster and simpler purification of histidine-tagged proteins 4
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... tube connectors, designed by an international standards process, will ... According to an invited review published in the OnlineFirst ... NCP ), the official journal of the American Society ... will greatly reduce the occurrence of misconnection that can ... connectors, which are used to join medical devices, components, ...
(Date:8/21/2014)... has successfully replicated one of the crucial steps in ... sunlight which could manufacture hydrogen as a fuel. , ... an exciting prospect to use them to create hydrogen, ... Hingorani, from the ARC Centre of Excellence for Translational ... Hydrogen offers potential as a zero-carbon replacement for petroleum ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2New feeding tube connectors will improve patient safety 2Water and sunlight the formula for sustainable fuel 2
... marker for Alzheimer,s disease rises and falls in the spinal ... researchers at Washington University School of Medicine in St. Louis ... young people and reinforces a link between increased Alzheimer,s risk ... The brain,s relative inactivity during sleep may provide an ...
... NEW YORK (Sept. 26, 2011) -- The National Institutes ... Research Project (T-R01) Award to fund research into risk factors ... area of the affected baby,s spine or brain is not ... Margaret Elizabeth Ross and Dr. Christopher E. Mason at Weill ...
... Rochelle, NY, September 26, 2011Magnetic resonance tractography (MRT) ... human brain anatomy and, as MRT methods and ... and illuminating information on brain activity and connectivity. ... this technology is explored in a forward-looking review ...
Cached Biology News:Marker for Alzheimer's disease rises during day and falls with sleep 2Marker for Alzheimer's disease rises during day and falls with sleep 3NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 3
...
... Endogenous potent vasoconstrictor peptide. Displays selectivity ... vascular tonus. ET-1, ET-2, and ET-3 are ... ET-2 and ET-3 are similar to ET-1, ... acids, respectively. All three isopeptides produce strong ...
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... include subcloning of gene in baculoviral ... isolation and plaque purification of ten ... stock for one clone, protein expression ... cell culture. Expected yield and timeline: ...
Biology Products: